 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || 101BHG-D01 / Beijing Shuobai Pharma
PK/PD data, Preclinical, Journal: Pharmacokinetics, Mass Balance, Tissue Distribution and Metabolism of [14C]101BHG-D01, a Novel Muscarinic Receptor Antagonist, in Rats. (Pubmed Central) - Jan 8, 2024
In conclusion, the study results are useful for better understanding the pharmacokinetic profiles of 101BHG-D01 and provide a robust foundation for subsequent clinical studies.
- | 101BHG-D01 / Beijing Shuobai Pharma
Preclinical, Journal: Effects of 101BHG-D01, a novel M receptor antagonism, on allergic rhinitis in animal models and its mechanism. (Pubmed Central) - Aug 14, 2023
Furthermore, IL-13 stimulation significantly increased JAK1 and STAT6 phosphorylation, which was suppressed by 101BHG-D01. We demonstrated that 101BHG-D01 reduced mucus secretion and inflammatory cell infiltration in the nasal mucosa, which may occur through a reduction in activation of the JAK1-STAT6 signaling pathway, indicating that 101BHG-D01 is a potent and safe anticholinergic therapy for AR.
- | 101BHG-D01 / Beijing Shuobai Pharma
Journal: Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its main metabolite M6 in human plasma, urine and feces: Application to a clinical study in healthy Chinese subjects. (Pubmed Central) - Jun 12, 2023
The cumulative urinary and fecal excretion rates revealed 101BHG-D01 was mainly excreted in feces, rather than urine. The pharmacokinetic results of the study drug laid a foundation for its further clinical development.
- || 101BHG-D01 / Beijing Shuobai Pharma
Clinical, PK/PD data, Journal: Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects. (Pubmed Central) - Jan 3, 2023
The study results indicate that 101BHG-D01 is a good candidate for the treatment of COPD and enable further clinical development in subsequent studies in patients. Clinical Trial Registration: http://www.chinadrugtrials.org.cn; Identifier: CTR20192058.